Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: Contribution of histamine H1 receptor blockade

Frontiers in Psychiatry

Volumn 3, Issue MAY, 2012, Pages

  Fell, Matthew J ^a,b   Katner, Jason S ^a   Rasmussen, Kurt ^a   Nikolayev, Alexander ^a   Kuo, Ming Shang ^a   Nelson, David L G ^a   Perry, Kenneth W ^a   Svensson, Kjell A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antipsychotic; Clozapine; Fmpd; Histamine; In vivo microdialysis; Olanzapine

Indexed keywords

8 FLUORO 4 [3 (2 METHOXYETHYL) 4 METHYL 1 PIPERAZINYL] 2 METHYL 10H THIENO[2,3 B][1,5]BENZODIAZEPINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H3 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BRAIN LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; IN VIVO STUDY; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; RAT; RECEPTOR BLOCKING;

EID: 84867116222     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2012.00049     Document Type: Article

References (38)

1. Assié, M. B., Ravailhe, V., Faucil-lon, V., and Newman-Tancredi, A. (2005). Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemi-cal profile of novel antipsychotics: frontocortical dopamine and hip-pocampal serotonin release in rat brain. J. Pharmacol. Exp. Ther. 315, 265-272.
2. Barth, V. N., Chernet, E., Martin, L. J, Need, A. B., Rash, K. S., Morin, M., and Phebus, L. A. (2006). Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclo-pride tracer. Life Sci. 78, 3007-3012.
3. Bentley, J. C., Bourson, A., Boess, F. G., Fone, K. C., Marsden, C. A., Petit, N., and Sleight, A. J. (1999). Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. Br. J. Pharmacol. 126, 1537-1542.
4. Bøgesø, K. P., Arnt, J., Boeck, V., Chris-tensen, A. V., Hyttel, J., and Jensen, K. G. (1988). Antihypertensiveactivity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity. J. Med. Chem. 31, 2247-2256.
5. Bymaster, F., Perry, K. W., Nelson, D. L., Wong, D. T., Rasmussen, K., Moore, N. A., and Calligaro, D. O. (1999). Olanzapine: a basic science update. Br. J. Psychiatry Suppl. 37, 36-40.
6. Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., and Wong, D. T. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96.
7. Eriksson, K. S., Stevens, D. R., and Haas, H. L. (2001). Serotonin excites tuberomam-millary neurons by activation of Na(+)/Ca(2+)-exchange. Neuropharmacology 40, 345-351.
8. Fell, M. J., Katner, J. S., Johnson, B. G., Khilevich, A., Schkeryantz, J. M., Perry, K. W., and Svensson, K. A. (2010). Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute keta-mine challenge. Neuropharmacology 58, 632-639.
9. Ghoneim, O. M., Legere, J. A., Golbraikh, A., Tropsha, A., and Booth, R. G. (2006). Novel ligands for the human histamine H1 receptor: synthesis, pharmacology, and comparative molecular field analysis studies of 2-dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes. Bioorg. Med. Chem. 14, 6640-6658.
10. Goudie, A. J., Smith, J. A., and Millan, M. J. (2004). Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiap-ine. Psychopharmacology (Berl.) 171, 212-222.
11. Haas, H., and Panula, P. (2003). The role of histamine and the tuberomam-millary nucleus in the nervous system. Nat. Rev. Neurosci. 4, 121-130.
12. Haas, H. L., Sergeeva, O. A., and Selbach, O. (2008). Histamine in the nervous system. Physiol. Rev. 88, 1183-1241.
13. Huang, M., Li, Z., Dai, J., Shahid, M., Wong, E. H., and Meltzer, H. Y. (2008). Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 33, 2934-2945.
14. Kapur, S., VanderSpek, S. C., Brown-lee, B. A., and Nobrega, J. N. (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol Exp. Ther. 305, 625-631.
15. Keefe, R. S., Bilder, R. M., Davis, S. M., Harvey, P. D., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Capuano, G., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Davis, C. E., Hsiao, J. K., and Lieberman, J. A. (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 633-647.
16. Kuroki, T., Meltzer, H. Y., and Ichikawa, J. (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol Exp. Ther. 288, 774-781.
17. Laitinen, K. S. M., Tuomisto, L., and Laitinen, J. T. (1995). Endogenous serotonin modulates histamine release in the rat hypothalamus as measured by in vivo microdialysis. Eur. I Pharmacol. 285, 159.
18. Le, S., Gruner, J. A., Mathiasen, J. R., Marino, M. J., and Schaffhauser, H. (2008). Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J. Pharmacol. Exp. Ther. 325, 902-909.
19. Li, X. M., Perry, K. W., Wong, D. T., and Bymaster, E P. (1998). Olanzap-ine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl). 136, 153-161.
20. Lovenberg, T. W., Pyati, J., Chang, H., Wilson, S. J., and Erlander, M. G. (2000). Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles. J. Pharmacol. Exp. Ther. 293, 771-778.
21. Marek, G. J., Martin-Ruiz, R., Abo, A., and Artigas, E. (2005). The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 30, 2205-2215.
22. Meltzer,H.Y.,and McGurk, S.R. (1999). The effects of clozapine, risperi-done, and olanzapine on cognitive function in schizophrenia. Schizo-phr. Bull. 25, 233-255.
23. Meltzer, H. Y., and Okayli, G. (1995). Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry 152, 183-190.
24. Morisset, S., Sahm, U. G., Traiffort, E., Tardivel-Lacombe, J., Arrang, J. M., and Schwartz, J. C. (1999). Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine 2a receptor blockade. J. Pharmacol. Exp. Ther. 288, 590-596.
25. Natesan, S., Reckless, G. E., Nobrega, J. N., Fletcher, P. J., and Kapur, S. (2006). Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31, 1854-1863.
26. Pehek, E. A., Nocjar, C., Roth, B. L., Byrd, T. A., and Mabrouk, O. S. (2006). Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31, 265-277.
27. Peroutka, S. J., Synder, S. H., and Snyder, S. H. (1980). Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Am. J. Psychiatry 137, 1518-1522.
28. Perry, K. W., Falcone, J. F., Fell, M. J., Ryder, J. W., Yu, H., Love, P. L., Kat-ner, J., Gordon, K. D., Wade, M. R., Man, T., Nomikos, G. G., Phebus, L. A., Cauvin, A. J., Johnson, K. W., Jones, C. K., Hoffmann, B. J., Sandusky, G. E., Walter, M. W., Porter, W J., Yang, L., Merchant, K. M., Shannon, H. E., and Svensson, K. A. (2008). Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neu-ropharmacology 55, 743-754.
29. Rasmussen, K., Benvenga, M. J., Bymaster, E P., Calligaro, D. O., Cohen, I. R., Falcone, J. F., Hemrick-Luecke, S. K., Martin, E M., Moore, N. A., Nisenbaum, L. K., Schaus, J. M., Sundquist, S. J., Tupper, D. E., Wiernicki, T. R., and Nelson, D. L. (2005). Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. J. Pharmacol. Exp. Ther. 315, 1265-1277.
30. Roth, B. L., Craigo, S. C., Choud-hary, M. S., Uluer, A., Monsma, E J. Jr., Shen, Y., Meltzer, H. Y., and Sibley, D. R. (1994). Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268, 1403-1410.
31. Roth, B. L., Lopez, E., Beischel, S., Westkaemper, R. B., and Evans, J. M. (2004). Screening the recep-torome to discover the molecular targets for plant-derived psy-choactive compounds: a novel approach for CNS drug discovery. Pharmacol. Ther. 102, 99-110.
32. Schwartz, J. C., Arrang, J. M., Garbarg, M., Pollard, H., and Ruat, M. (1991). Histaminergic transmission in the mammalian brain. Physiol. Rev. 71, 1-51.
33. Seeman, P., Corbett, R., and Van Tol, H. H. (1997). Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16, 93-110; discussion 111-135.
34. Seeman, P., and Lee, T. (1975). Antipsychotic drugs: direct correlation between clinical potency and presy-naptic action on dopamine neurons. Science 188, 1217-1219.
35. Wainscott, D. B., Lucaites, V. L., Kursar, J. D., Baez, M., and Nelson, D. L. (1996). Pharmaco-logic characterization of the human 5-hydroxytryptamine 2B receptor: evidence for species differences. J. Pharmacol. Exp. Ther. 276, 720-727.
36. Westerink, B. H., Cremers, T. I., De Vries, J. B., Liefers, H., Tran, N., and De Boer, P. (2002). Evidence for activation of histamine H3 autoreceptors during handling stress in the prefrontal cortex of the rat. Synapse 43, 238-243.
37. Zeng, X. P., Le, F., and Richelson, E. (1997). Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur. J. Pharmacol. 321, 349-354.
38. Zhang, W., Perry, K. W., Wong, D. T., Potts, B. D., Bao, J., Tollefson, G. D., and Bymaster, E P. (2000). Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23, 250-262.